Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- ADTRAN, Inc. (ADTN) Tops Q4 EPS by 10c
- Citigroup (C) Tops Q4 EPS by 2c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!